Filing Details
- Accession Number:
- 0000950170-25-017031
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-10 16:05:06
- Reporting Period:
- 2025-02-10
- Accepted Time:
- 2025-02-10 16:05:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 2036042 | Sionna Therapeutics Inc. | SION | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1357522 | A. Peter Thompson | Sionna Therapeutics, Inc. 21 Hickory Drive, Suite 500 Waltham MA 02451 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-02-10 | 3,154,959 | $0.00 | 3,154,959 | No | 4 | C | Indirect | By OrbiMed Private Investments VIII, LP |
| Common Stock | Acquisiton | 2025-02-10 | 550,000 | $18.00 | 3,704,959 | No | 4 | P | Indirect | By OrbiMed Private Investments VIII, LP |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By OrbiMed Private Investments VIII, LP |
| No | 4 | P | Indirect | By OrbiMed Private Investments VIII, LP |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B convertible preferred stock | Disposition | 2025-02-10 | 2,560,951 | $0.00 | 1,752,755 | $0.00 |
| Common Stock | Series C convertible preferred stock | Disposition | 2025-02-10 | 2,048,760 | $0.00 | 1,402,204 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.
- The securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
- Each of OrbiMed Advisors, GP VIII and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
- Reflects shares purchased in the Issuer's initial public offering.
Billionaire Hedge Funds
